GW Pharmaceuticals’ Cannabis-derived drug shows promise in brain cancer trial
GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol…
Read More...
Read More...
